XML 20 R3.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Balance Sheets - USD ($)
Sep. 30, 2025
Sep. 30, 2024
Current Assets:    
Cash and cash equivalents $ 4,252,290 $ 3,251,880
Inventory 22,286,693 8,268,766
Prepaid expenses 1,395,490 2,700,000
Total Current Assets 27,934,473 14,220,646
Operating lease right-of-use asset, net 818,694 246,247
Other Assets:    
Deposits 38,062 38,062
In-process research and development 92,800,000 92,800,000
Goodwill 9,346,796 9,346,796
Total Other Assets 102,184,858 102,184,858
Total Assets 130,938,025 116,651,751
Current Liabilities:    
Accounts payable 13,693,692 4,927,211
License payable 22,650,000 28,400,000
Accrued expenses 4,190,253 17,027
Accrued compensation 3,292,447 2,229,018
Note payable 1,000,000
Operating lease liability 88,348 241,547
Total Current Liabilities 44,914,740 35,814,803
Deferred tax liability 7,770,760 6,713,800
Operating lease liability – non current 724,925 21,318
Total Liabilities 53,410,425 42,549,921
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 250,000,000 and 16,000,000 shares authorized at September 30, 2025 and 2024, respectively; 18,067,744 and 7,247,243 shares issued and outstanding at September 30, 2025 and 2024, respectively 18,068 7,247
Additional paid-in capital 306,336,239 271,440,421
Accumulated deficit (238,804,129) (201,370,218)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 67,550,178 70,077,450
Non-controlling interest 9,977,422 4,024,380
Total Equity 77,527,600 74,101,830
Total Liabilities and Equity $ 130,938,025 $ 116,651,751